With 0.78 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.07 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $45.51 whereas the lowest price it dropped to was $42.84. The 52-week range on SRRK shows that it touched its highest point at $46.19 and its lowest point at $6.76 during that stretch. It currently has a 1-year price target of $46.38. Beta for the stock currently stands at 0.53.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SRRK was down-trending over the past week, with a drop of -3.07%, but this was up by 16.33% over a month. Three-month performance surged to 500.82% while six-month performance rose 468.34%. The stock gained 152.34% in the past year, while it has gained 2.17% so far this year. A look at the trailing 12-month EPS for SRRK yields -2.47 with Next year EPS estimates of -2.22. For the next quarter, that number is -0.60. This implies an EPS growth rate of -22.05% for this year and 8.47% for next year.
Float and Shares Shorts:
At present, 80.08 million SRRK shares are outstanding with a float of 71.51 million shares on hand for trading. On 2024-12-13, short shares totaled 15.07 million, which was 1610.0000000000002 higher than short shares on 1731628800. In addition to Dr. Jay Thomas Backstrom M.D., M.P.H. as the firm’s President, CEO & Director, Mr. Edward H. Myles MBA serves as its CFO, COO & Treasurer.
Institutional Ownership:
Through their ownership of 0.98514 of SRRK’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, SRRK reported revenue of $0.0 and operating income of -$64780000.0. The EBITDA in the recently reported quarter was -$64334000.0 and diluted EPS was -$0.66.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SRRK since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SRRK analysts setting a high price target of 57.0 and a low target of 33.0, the average target price over the next 12 months is 46.375. Based on these targets, SRRK could surge 29.08% to reach the target high and fall by -25.27% to reach the target low. Reaching the average price target will result in a growth of 5.02% from current levels.
Analysts have provided yearly estimates in a range of -$2.23819 being high and -$2.54933 being low. For SRRK, this leads to a yearly average estimate of -$2.42889.
